Business Overview Financial Summary

China Antibody Pharmaceutical is a Hong Kong biopharmaceutical company that specializes in the research, development, manufacture and commercialization of therapies for immune diseases. It mainly develops biopharmaceuticals based on monoclonal antibodies. In October 2019, the Group's product portfolio included 2 drugs under development for the treatment of multiple immune diseases at different clinical trial levels and 4 drugs under development at the new drug research level. The goal of these drugs in research is to treat RA, systemic lupus erythematosus (SLE), asthma, pemphigus, dry syndrome (SS), and other immune diseases. The group has a production base in Haikou City, Hainan Province, and has also built a commercial-scale production facility in Suzhou City, Jiangsu Province.

Competitive advantage

The Group is one of the few biopharmaceutical companies with a fully developed, comprehensive platform in the Greater China region

The Group has an ever-expanding portfolio of drugs being developed to treat immune diseases, targeting a market with great potential for growth

Risk Factors

The group currently does not generate revenue from commercial sales of pharmaceuticals. It may not be able to generate profits according to expectations, or it may not be profitable at all

The Group is a company on the development stage. It may be difficult to evaluate current business and predict future results

Use of proceeds

Approximately 50% is used for R&D and commercialization in research drugs

About 40% is used as a production base in Suzhou

Approximately 10% is used as general working capital